ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint742,806 companies indexed · Last updated: today
DirectoryIndustryMedical Technology IndustryZugCellis AG
Cellis AG Logo
Verified· 2 sources

Cellis AG

Summary

About the company

The core activity of Cellis is the development of cell-based cancer treatments, in particular through the application of a platform technology that enables targeted delivery of active substances directly into cancer cells and modifies the tumor microenvironment to inhibit the growth of cancer cells.

AI-generated
Offering

Products & services

Industry:Medical Technology IndustryPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered5
Cell-based oncology therapy
Cell-based oncology therapy for solid tumors, centered on macrophage drug conjugates, targeted delivery of active compounds, and development toward clinical trials.
Macrophage-Drug Conjugate (MDC) technology
Macrophage-drug conjugate platform for solid tumors, using macrophages loaded with ferritin-drug complexes to deliver immunomodulators, inhibitors, cytotoxic drugs, radioisotopes or peptides.
Preclinical research and development
Preclinical research on MDC technology, validation in cell and animal models, TRAIN mechanism of action, tumour penetration, drug release, and safety in solid tumors.
Development of cell therapies for solid tumors
Development of allogeneic, ready-to-use cell therapies for glioblastoma, ovarian cancer, pancreatic cancer, head and neck cancer and other solid tumors.
Clinical development of MDC-735
Preparation and clinical development of the MDC-735 therapy, including GMP manufacturing, regulatory submission documents and Phase I studies for solid tumors.

Knowledge

No knowledge articles yet

Once Cellis AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Cellis AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Cellis AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Cellis AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Gubelstrasse 15
6300 Zug

At a glance

Legal form
Corporation
UID
CHE-163.192.615
Founded
2024 · 2 years
Last commercial register change
December 24, 2025
Employees
1 to 10

Similar companies

MB
MOHE BioTech (Suisse) SA
Zug
OA
Ortholab AG
Zug
AP
Angelini Pharma S.p.A., Rom, Zweigniederlassung Zug
Zug
PP
PHT Pharmaceutical AG
Baar